MedTrace Logo

Methadone Maintenance Treatment and Smoking Cessation

NCT00906386 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2010-03-02

No results posted yet for this study

Summary

The main hypotheses guiding the study are:

1. Stable methadone maintenance patients receiving varenicline will be more likely to maintain abstinence than patients receiving placebo
2. There will be no differences in the type and number of symptoms reported between stable methadone maintenance patients receiving varenicline and placebo
3. There will be no changes in methadone dosage between abstinent and non-abstinent smokers
4. There will be no differences in efficacy, withdrawal symptoms, and safety of varenicline between male and female participants

Conditions

  • Smoking

Interventions

DRUG

Varenicline

oral, 1 mg twice daily, 12 weeks

DRUG

placebo

oral, 1 mg twice daily, 12 weeks

Sponsors & Collaborators

  • British Columbia Centre of Excellence for Women's Health

    collaborator UNKNOWN

  • Vancouver Coastal Health

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2009-10-31
Completion
2011-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00906386 on ClinicalTrials.gov